



NDA 207500/S-011
NDA 207501/S-009

CORRECTED SUPPLEMENT APPROVAL

Astellas Pharma US Inc.
Attention: Robert M. Reed
Senior Director, Regulatory Affairs
1 Astellas Way
Northbrook, IL 60062

Dear Mr. Reed:

Please refer to your supplemental new drug applications (sNDAs) dated and received August 26, 2021, and your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Cresemba (isavuconazonium sulfate) capsules, 186 mg (NDA 207500), and Cresemba (isavuconazonium sulfate) for injection, 372 mg (NDA 207501).

We also refer to our approval letter dated February 17, 2022, which contained the following error: the wrong version of the blister label for Cresemba capsules, 186 mg was appended to the letter.

This corrected action letter incorporates the correction of the error. The effective date will remain February 17, 2022.

These Prior Approval sNDAs provide for revisions to the NDC numbers in the **HOW SUPPLIED/STORAGE AND HANDLING (16)** section, **How Supplied** (16.1) subsection, **Capsules** and **Injection** subheadings of the Prescribing Information (PI) and in the carton and container labeling. Additionally, minor editorial updates have been made throughout the PI and the Patient Package Insert (PPI).

APPROVAL & LABELING

We have completed our review of these applications, as amended. They are approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using

the FDA automated drug registration and listing system (eLIST), as described at FDA.gov.¹ Content of labeling must be identical to the enclosed labeling (text for the Prescribing Information and the Patient Package Insert), with the addition of any labeling changes in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling. Information on submitting SPL files using eList may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*.²

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for these NDAs, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in Microsoft Word format, that includes the changes approved in these supplemental applications, as well as annual reportable changes. To facilitate review of your submission(s), provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

CARTON AND CONTAINER LABELING

Submit final printed carton and container labeling that are identical to the enclosed carton and container labeling as soon as they are available, but no more than 30 days after they are printed. Please submit these labeling electronically according to the guidance for industry *Providing Regulatory Submissions in Electronic Format — Certain Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications*. For administrative purposes, designate this submission “**Final Printed Carton and Container Labeling for approved NDAs 207500/S-011 and 207501/S-009.**” Approval of this submission by FDA is not required before the labeling is used.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

¹ <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>

² We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database <https://www.fda.gov/RegulatoryInformation/Guidances/default.htm>.

NDA 207500/S-011

NDA 207501/S-009

Page 3

If you have any questions, call Alison Rodgers, Regulatory Project Manager, at 301-796-0797.

Sincerely,

{See appended electronic signature page}

Dmitri Iarikov, MD, PhD
Deputy Director
Division of Anti-Infectives
Office of Infectious Diseases
Center for Drug Evaluation and Research

ENCLOSURE(S):

- Content of Labeling
 - Prescribing Information
- Carton and Container Labeling

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

DMITRI IARIKOV
02/17/2022 06:17:02 PM